Moss Adams Wealth Advisors LLC Purchases 2,522 Shares of Johnson & Johnson (NYSE:JNJ)

Moss Adams Wealth Advisors LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 56.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 6,998 shares of the company’s stock after purchasing an additional 2,522 shares during the period. Moss Adams Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $1,134,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in JNJ. Innealta Capital LLC acquired a new stake in shares of Johnson & Johnson in the second quarter valued at $27,000. MFA Wealth Advisors LLC acquired a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $43,000. Fairfield Financial Advisors LTD bought a new position in Johnson & Johnson in the 2nd quarter worth approximately $46,000. Fairway Wealth LLC lifted its holdings in Johnson & Johnson by 217.1% during the 2nd quarter. Fairway Wealth LLC now owns 333 shares of the company’s stock worth $49,000 after buying an additional 228 shares in the last quarter. Finally, Quarry LP bought a new position in Johnson & Johnson in the 2nd quarter valued at $49,000. 69.55% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

JNJ stock opened at $165.13 on Friday. The company’s 50-day moving average price is $162.98 and its two-hundred day moving average price is $154.71. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The firm has a market cap of $397.41 billion, a P/E ratio of 10.29, a P/E/G ratio of 2.65 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company’s revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.66 EPS. On average, analysts anticipate that Johnson & Johnson will post 10 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.00%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday. Citigroup upped their target price on shares of Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. TD Securities dropped their price objective on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Finally, Morgan Stanley raised their target price on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday. Six research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $175.93.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.